Efficacy of Combination Chemotherapy with Amlodinib and Paclitaxel Combined with Cisplatin in the Treatment of Advanced Non-small Cell Lung Cancer
Objective To explore the application effect of the combination of amlodinib and paclitaxel with cisplatin chemotherapy regimen in the treatment of advanced non-small cell lung cancer(NSCLC)patients.Methods A total of 62 patients with NSCLC in Xinyang Central Hospital from February 2019 to February 2021 were selected and divided into two groups with 31 patients in each group by random number table method.The control group received paclitaxel combined with cisplatin regimen treatment,while the study group received alotinib treatment on the basis of the control group.The short-term efficacy,the levels of tumor cell growth factors[matrix metalloproteinase-9(MMP-9),vascular endothelial growth factor(VEGF),basic fibroblast growth factor(BFGF)]before and after treatment,the cellular immune function[T lymphocytes(CD3+,CD4+,CD8+),CD4+/CD8+],survival time,quality of life and toxic and side effects were compared between the two groups.Results The object response rate and disease control rate of the study group were higher than those of the control group(P＜0.05).After treatment,the levels of CD3+,CD4+,CD4+/CD8+in the study group were higher than those in the control group,while the levels of MMP-9,VEGF,BFGF and CD8+in the study group were lower than those in the control group(P＜0.05).The progression free survival and overall survival of the study group were longer than those of the control group(P＜0.05).After treatment,the functional assessment of cancer therapy-lung score of the study group was higher than that of the control group,while the European organization for research and treatment of cancer quality of life core questionnaire score was lower than that of the control group(P＜0.05).There was no statistically difference in the incidence of complications between the two groups(P＞0.05).Conclusion The combination of amlotinib and paclitaxel with cisplatin chemotherapy has a definite effect on the treatment of advanced NSCLC,which can inhibit tumor cell growth,reduce immune function damage,prolong patient survival,and improve quality of life.
non-small cell lung canceranrotinibpaclitaxelcisplatintumor cell growth factorcellular immune function
万方数据
维普
